TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10753248
Drug: Spacer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spacer group (albuterol 600 microg by MDI with spacer)
Study: 10753248
Drug: Nebulizer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer group (2.5 mg albuterol by nebulizer)
Study: 8884922
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of CoQ10
Study: 1362841
Drug: Dithranol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol 2% ointment applied once daily for 8 weeks
Study: 1362841
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied once daily for 8 weeks
Study: 1362841
Drug: Dithranol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol treatment
Study: 29782641
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone 0.1 mg·kg-1
Study: 29782641
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone 0.1 mg·kg-1
Study: 23137512
Drug: NT-proBNP guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP guided care aiming to reduce NT-proBNP values ≤1000 pg/mL
Study: 20381658
Drug: DM treatment
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DM treatment intensification for suboptimal control (HbA(1c) 7% to 9%)
Study: 20381658
Drug: DM treatment
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DM treatment intensification for poor control (HbA(1c) >9%)
Study: 18431346
Drug: MC-1 250
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-1 250 mg/day
Study: 18431346
Drug: MC-1 750
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-1 750 mg/day
Study: 7737776
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 3 months
Study: 7737776
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg for 3 months
Study: 2044924
Drug: 0.1N hydrochloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1N hydrochloric acid infusion
Study: 2044924
Drug: Autologous duodenal
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous duodenal secretions infusion
Study: 6291739
Drug: Daily radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily radiotherapy (5000 rad in 25 fractions in 5 weeks)
Study: 6291739
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (hyperfractionation and daily regimens)
Study: 6291739
Drug: Hyperfractionation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionation with chemotherapy
Study: 25616431
Drug: Axitinib (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (in patients with prior sunitinib treatment)
Study: 15964483
Drug: RTS,S/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02A vaccine at 10 microg
Study: 15964483
Drug: RTS,S/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02A vaccine at 25 microg
Study: 15964483
Drug: RTS,S/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02A vaccine at 50 microg
Study: 11796658
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (Cr, 4 x 5 g/day, 4 days)
Study: 11796658
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (Caf, 5 mg x kg(‐1) x day(‐1), 3 days)
Study: 11796658
Drug: Acute caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute caffeine intake (ACaf, 5 mg/kg)
Study: 2404843
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered at 06.00
Study: 2404843
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered at 18.00
Study: 7298477
Drug: Therapies (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies (specific types not detailed)
Study: 31197861
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (FeSulf)
Study: 21640762
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg per day (AT group, n=52)
Study: 17195236
Drug: CAT-192 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAT-192 (10 mg/kg)
Study: 17195236
Drug: CAT-192 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAT-192 (5 mg/kg)
Study: 17195236
Drug: CAT-192 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAT-192 (0.5 mg/kg)
Study: 17195236
Drug: CAT-192 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAT-192 (all doses)
Study: 12686786
Drug: 1 mg/h
Normalized name: fentanyl 0.1 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/h nimodipine
Study: 12686786
Drug: 2 mg/h
Normalized name: nicotine 0.312 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/h nimodipine
Study: 12686786
Drug: High-dose nimodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nimodipine
Study: 10985616
Drug: Cetrorelix (LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (LHRH antagonist)
Study: 10985616
Drug: Buserelin (LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (LHRH agonist)
Study: 9368162
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (brief course of steroids)
Study: 1547059
Drug: Neostigmine 0.036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.036 mg kg‐1
Study: 1547059
Drug: Neostigmine 0.071
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.071 mg kg‐1
Study: 1547059
Drug: Edrophonium 1.43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1.43 mg kg‐1
Study: 3904908
Drug: diethylstilboestrol 3
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diethylstilboestrol 3 mg/day
Study: 3904908
Drug: estramustine 560
Approvals — FDA: no, EMA: no, PMDA: no
Description: estramustine 560 mg/day
Study: 27831636
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of dust mite drops, once per day, gradually increasing the dose to reach a high maintenance level.
Study: 27831636
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of dust mite drops
Study: 22541754
Drug: PF-00734200 10
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-00734200 10 mg single dose
Study: 22541754
Drug: PF-00734200 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00734200 100 mg single dose
Study: 22541754
Drug: PF-00734200 20
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-00734200 20 mg once daily for 6 days
Study: 18384853
Drug: Weekly postoperative
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly postoperative pelvic floor muscle training (PFMT) (Treatment)
Study: 15875528
Drug: Ciclesonide 640
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 640 microg twice daily
Study: 15875528
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 880 microg twice daily
Study: 10561630
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (6 g loading dose in 100 mL isotonic sodium chloride solution, followed by 2 g/h infusion for 3 hours at 125 mL/h)
Study: 10561630
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution (100 mL isotonic sodium chloride solution, similar infusion rate)
Study: 9046544
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment using specially designed compression pads, elevation of the injured foot (24 h), repeated elastic wrapping, early full weight-bearing and proprioceptive range-of-motion training (Group I, n = 46)
Study: 9046544
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with an elastic bandage, partial weight bearing and crutches until pain subsided (Group II, n = 40)
Study: 9046544
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (Group I)
Study: 9046544
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Group II)
Study: 1989755
Drug: Dantrolene sodium
Normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dantrolene sodium (2 mg/kg body weight iv)
Study: 6340700
Drug: pindolol (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (standard medication)
Study: 24819911
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose escalation scheme of dipyridamole
Study: 24819911
Drug: Slow dose
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow dose escalation scheme of dipyridamole
Study: 22802432
Drug: 2009 H1N1
Normalized name: influenza A virus A/California/7/2009 (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 H1N1 vaccine and seasonal TIV (TIV; split virion)
Study: 18540726
Drug: Decisional Balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decisional Balance Scale administered via computerized and paper versions
Study: 15785936
Drug: Ibuprofen co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen co-treatment
Study: 15785936
Drug: No ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No ibuprofen co-treatment (Control)
Study: 8775645
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.5 g.kg‐1 body weight)
Study: 8775645
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium carbonate, 0.5 g.kg‐1 body weight)
Study: 22235525
Drug: Prototype medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype medication drawer (Drawer 2)
Study: 22235525
Drug: Baseline medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline medication drawer (Drawer 1)
Study: 19516186
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blockers (CCB)
Study: 17410045
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2, day 1, every 3 weeks for eight cycles)
Study: 17410045
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 for cycles 1 and 2) followed by Gemcitabine (1200 mg/m2, days 1 and 8, every 3 weeks for cycles 3 and 4, repeated for a total of eight cycles)
Study: 3931467
Drug: Glyburide plus
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide plus insulin
Study: 26609786
Drug: Enoxaparin administered
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin administered through venous line
Study: 26609786
Drug: Enoxaparin administered
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin administered through arterial line
Study: 26609786
Drug: Venous line
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous line administration of enoxaparin
Study: 24921919
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment and surgery
Study: 19918972
Drug: Acetaminophen (4-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4-g bolus dose)
Study: 17852632
Drug: Step-down regimen
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down regimen (5.0 mg/kg per day starting dose and decreasing regimen)
Study: 17852632
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (2.5 mg/kg per day starting dose and increasing regimen)
Study: 10633202
Drug: Weekly ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly ferrous sulfate (60 mg elemental iron)
Study: 10633202
Drug: Daily ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily ferrous sulfate (60 mg elemental iron)
Study: 30476654
Drug: Colistin/rifampicin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin/rifampicin combination therapy
Study: 30476654
Drug: Colistin/rifampicin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin/rifampicin combination therapy with 'partial synergy'
Study: 30476654
Drug: Colistin/rifampicin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin/rifampicin combination therapy with 'indifferent' results
Study: 28412111
Drug: Apneic oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apneic oxygen insufflation (AOI) at 3 L/min for 30 minutes during one-lung ventilation (OLV)
Study: 25520389
Drug: Aspirin and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and/or NSAIDs
Study: 23840145
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (antox version 1.2-based)
Study: 17055622
Drug: Reformulated oral
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated oral cholera vaccine
Study: 7677828
Drug: Active allergen
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active allergen avoidance treatment (n = 17)
Study: 2904753
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 to 8 mg)
Study: 30918221
Drug: Serum TG
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum TG level <100 mg/dL
Study: 30918221
Drug: Serum TG
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum TG level ≥100 mg/dL
Study: 27778264
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus Chinese herbal medicines (CHMs) for benefiting qi and activating blood circulation
Study: 18434639
Drug: 2.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/day mycophenolate mofetil (MMF) plus 20 mg/day prednisone
Study: 18434639
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 20 mg/day prednisone
Study: 17057572
Drug: Laparoscopic cholecystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cholecystectomy (group L)
Study: 13677549
Drug: Loestrin Fe
Normalized name: Lo Loestrin Fe
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Loestrin Fe 1/20 (norethindrone acetate 1 mg/EE 20 microg)
Study: 8874906
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 micrograms . kg‐1) administered 1.5 hr before surgery, and at 12 hr and 24 hr after initial dose
Study: 1411952
Drug: 24-hour treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour treatment (cefoxitin or cefotetan)
Study: 1411952
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment
Study: 1411952
Drug: 24-hour treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour treatment (cefoxitin or cefotetan) in high-risk group (colon wounds)
Study: 1411952
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment in high-risk group (colon wounds)
Study: 1411952
Drug: 24-hour treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour treatment (cefoxitin or cefotetan) in high-risk group (ATI > 25)
Study: 1411952
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment in high-risk group (ATI > 25)
Study: 2932705
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (group B)
Study: 2932705
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg (group C)
Study: 28716141
Drug: Multicomponent activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent activation therapy for people with MCI or mild to moderate dementia and a brief telephone intervention for informal caregivers.
Study: 28716141
Drug: Multicomponent activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent activation therapy and caregiver counselling.
Study: 23945510
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine 1 μg/kg
Study: 22042184
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CT)
Study: 19364334
Drug: Venom Immunotherapy
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venom Immunotherapy (VIT)
Study: 9048792
Drug: Epinephrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (1 mg intravenously)
Study: 8328080
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 micrograms twice daily)
Study: 8328080
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (750 micrograms twice daily)
Study: 3551508
Drug: Antacid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid treatment (10 ml of an antacid suspension, buffering capacity 85 mmol/10 ml, administered 1 and 3 hours after each meal and at bedtime)
Study: 27178435
Drug: Bitopertin 3
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 3 mg
Study: 27178435
Drug: Bitopertin 10
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 10 mg
Study: 27178435
Drug: Bitopertin 60
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 60 mg
Study: 27178435
Drug: RG7118 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7118 15 mg
Study: 27178435
Drug: RG7118 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7118 30 mg
Study: 9143608
Drug: D0870 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D0870 (50 mg initial dose followed by 10 mg for 4 days)
Study: 9143608
Drug: D0870 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D0870 (100 mg initial dose followed by 25 mg for 4 days)
Study: 9143608
Drug: D0870 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D0870 (100 mg initial dose followed by 10 mg for 5 days)
Study: 8196572
Drug: Mexiletine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (450 mg per day)
Study: 3310504
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose solution (dextrose group)
Study: 3310504
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution (Hartmann group)
Study: 3310504
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous infusion (control group)
Study: 16389065
Drug: Individualized (broad)
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized (broad) cognitive behavioral therapy
Study: 16389065
Drug: Manual‐based (focused)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual‐based (focused) cognitive behavioral therapy
Study: 11251036
Drug: Hydrocortisone infusion
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusion (100 mg followed by continuous infusion of 0.18 mg/kg per h)
Study: 9235736
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 2.0 IU/m2, Norditropin
Study: 22230409
Drug: Lactobacillus salivarius
Normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus salivarius LS01 (probiotic treatment)
Study: 9405729
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 group (vitamin D3 300 IU/day + calcium lactate 500 mg/day)
Study: 9405729
Drug: HRT +
Normalized name: Hormone Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT + Vit D3 group (2 mg estradiol valerate + 1 mg cyproterone acetate + vitamin D3 300 IU/day + calcium lactate 500 mg/day)
Study: 9405729
Drug: HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group (2 mg estradiol valerate + 1 mg cyproterone acetate)
Study: 9405729
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (calcium lactate 500 mg/day)
Study: 9405729
Drug: Non-hormone groups
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormone groups (Vit D3 and placebo)
Study: 9405729
Drug: Hormone groups
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone groups (HRT and HRT + Vit D3)